At the frontiers of science, boundaries are meant to be crossed

In the science of cardiac electrophysiology, there is no sign that says, “Knowledge stops here.” Even if there were, Texas Cardiac Arrhythmia would regard it only as a marker showing the need for continued exploration and discovery.

Research is the heartbeat of the future. That’s why TCA’s staff includes professionals whose only work is to move the science forward. TCA conducts clinical research studies into the refinement of procedures like catheter-based ablation and the development of new technologies like those used in the treatment of heart failure patients.

Leadership in research gives TCA physicians a solid base from which to explore and help shape the future of electrophysiology. It gives TCA patients and people everywhere who have heart rhythm disorders the prospect of improved management of arrhythmia.

TCA. World leadership deep in the heart of Texas.

Advancing the Science: TCA Research Studies

To learn about current TCA research studies, click on any heading.

ABLATE-CRT - Catheter Ablation of Arrhythmias to Improve CRT Response

This is a multicenter open-label randomized control study that will compare anti-arrhythmia medications against ablation therapy to determine which therapy is better at treating arrhythmias in order to allow the heart to beat properly and respond to cardiac resynchronization therapy (CRT). This study will enroll patients that currently have a CRT device for treatment of heart failure and are experiencing one of the following abnormal heart rhythms (arrhythmias): Atrial Fibrillation/Flutter (AF/AFL), Supraventricular Tachycardia (SVT), Premature Ventricular Contractions (PVCs) or Ventricular Tachycardia (VT).

aMAZE - Left Atrial Appendage Ligation with the LARIAT+®Suture Delivery Systemas Adjunctive Therapy to Pulmonary Vein Isolation for Persistent or Longstanding Persistent Atrial Fibrillation

The left atrial appendage (LAA) is a small sac about the size of your thumb that hangs off the left atrium. It may add to the abnormal heart rhythm of atrial fibrillation (AF). This study is looking at adding the newer non-surgical procedure to close the LAA when combined with catheter ablation for AF. By closing the LAA, it is hoped that this may treat AF more effectively as compared to catheter ablation alone. This study involves a device called the LARIAT+ Suture Delivery System (or “LARIAT”) to close the LAA. The purpose of this study is to evaluate the safety and effectiveness of the LARIAT in subjects with Persistent and Longstanding Persistent AF.

Arrhythmogenic Substrate Evaluation and Ablation in Brugada Syndrome

This study will further investigate electrical conduction associated with Brugada Syndrome, and determine whether ablation may provide protection against VT/VF. In this case-controlled trial, 10 patients with a spontaneous type I Brugada ECG pattern will undergo empiric epicardial electrophysiological mapping and possibly radiofrequency ablation if fragmented epicardial potentials are identified.

AWARE - Impact of anxiety on cardiac substrate modification in woman with atrial fibrillation undergoing catheter ablation

Research studies have suggested an association between anxiety disorders and increased risk of AF. This risk is believed to be attributed to chronic inflammation resulting from anxiety which may cause changes in the heart tissue. These inflammatory changes in the heart tissue may initiate non-PV triggers and scar formation in the left atrium (LA – left upper chamber of the heart). Non-PV triggers and LA scar are known risk factors for recurrence of AF after ablation.

The purpose of this study is to evaluate the impact of anxiety on the heart tissue changes leading to non-PV triggers and LA scar in patients after AF ablation.

BIPOLAR VT - Bipolar Catheter Ablation for the Treatment of Refractory Scar-Related Ventricular Arrhythmia

This is a prospective, multi-center, non-randomized, un-blinded, observational trial for patients who are scheduled to undero treatment for ventricular tachycardia (VT). There are various approaches to treating VT, including ablation. During ablation, heat is usually delivered using a unipolar catheter, in which energy travels from the catheter tip to a grounding pad. This research study seeks to find out if a bipolar ablation catheter, in which the energy travels between two catheter tips on either side of the heart muscle, can be used to eliminate the arrhythmia when the unipolar ablation is unsuccessful.

Boehringer Ingelheim GLORIA - Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients with Atrial Fibrillation

Our research group is collaborating with Texas Heart and Vascular – Austin on this study. This global, multi-center, prospective Registry Program will investigate patients with newly diagnosed non-valvular Atrial Fibrillations (AF) at risk for stroke. The study seeks to investigate the patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke, and will collect real world data on important antithrombotic treatments for the prevention of stroke. This is an observational study, which means this study will only be collecting information on the medical treatment you are already receiving from your doctor for AF.

Brigham and Women's Hospital CIRT - Cardiovascular Inflammation Reduction Trial

Our research group is collaborating with Texas Heart and Vascular – Austin on this study. This is a randomized, double-blind, placebo-controlled, event-driven trial to determine if methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome who have already had at least one heart attack or have major blockages in more than one coronary artery found on a heart catheterization.

The U.S. Food and Drug Administration (FDA) has approved methotrexate to treat adults with rheumatoid arthritis and other diseases. However, methotrexate has not been approved to prevent heart attacks and strokes. Therefore, the use of methotrexate in this study is experimental.

CardioFocus Heartlight - Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System–Adaptive Contact

The purpose of this research study is to test the safety and effectiveness of the Cardiofocus Endoscopic Ablation System with Adaptive Contact (EAS-AC) when used to treat atrial fibrillation (AF). The investigational EAS-AC catheter uses laser energy. This differs from standard catheters which use radiofrequency as the energy source. Heat from the laser energy results in the destruction of a portion of the heart muscle that is essential for starting or maintaining the paroxysmal AF (PAF). The study will enroll patients who are scheduled to undergo an ablation procedure to treat AF.

This study is currently in follow-up only and is not enrolling new patients.

CHAMP-HF - Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction

Our research group is collaborating with Texas Heart and Vascular – Austin on this study. This study is sponsored by the pharmaceutical company named Novartis Pharmaceuticals Corporation. Novartis is conducting this non-interventional or observational study to understand how patients with heart failure are treated through evaluation of treatment patterns and reasons for treatment changes.

A non-interventional study is a study in which individuals are observed and certain outcomes are measured. Novartis invites you to join in this non-interventional study. The intention of this study is to provide insight into the treatment patterns of US patients receiving different heart failure treatments. About 5,000 patients in the United States will participate in the study.

Chronic Atrial Fibrillation and Exercise Tolerance

The purpose of this study is to determine whether pulmonary vein isolation with radiofrequency ablation will improve exercise capacity and endothelial function in patients with chronic atrial fibrillation. We hypothesize that exercise capacity and endothelial function will improve in patients with chronic atrial fibrillation following pulmonary vein isolation. This pilot study will compare exercise capacity via a treadmill stress test, arterial stiffness, endothelial function, and quality of life before and after PVI ablation.

COGNITION - Mild cognitive impairment (MCI) in patients with atrial fibrillation (AF), trajectories of the progression of MCI and factors associated with the progression

The purpose of this study is to evaluate the incidence of cognitive impairment in AF and compare two treatment strategies: anti-arrhythmic drugs (AADs) and ablation. Questionnaires will be used to evaluate your cognitive status.

CVRx Barostim Neo® – Baroreflex Activation Therapy® for Heart Failure

The purpose of this research study is to show whether the Barotim Neo device is safe and works in people with heart failure. The Neo system is a device that is designed to stimulate the body’s natural cardiovascular regulators called baroreceptors, which are in the large blood vessels (carotid arteries) in your neck and potentially improve your heart failure condition. It is believed that when the baroreceptors are stimulated, signals are sent to the brain. The brain then sends signals to the body telling the blood vessels to relax, the heart to slow the heartbeat and stop production of stress-related hormones in the heart, and the kidneys to reduce the amount of fluid in the body.

CyberHeart’s cardiac arrhythmia ablation treatment: Patients with Refractory Ventricular Tachycardia/Fibrillation

This study is a two center, non-randomized, open-label clinical trial that will use the Cyberknife® system and CyberHeart software to treat ventricular tachycardia (VT). The trial is being conducted to learn if this ablation approach is a viable alternative to catheter ablation for arrhythmias (abnormal heart rhythms), especially when conventional therapies with drugs or catheters have either failed or cannot be used. The study will enroll patients that have VT that cannot be treated by standard catheter ablation and have exhausted all conventional therapies for this arrhythmia.

DECAF II - Determining the association of chromosomal variants with non-PV triggers and ablation-outcome in AF

Atrial Fibrillation (AF) often occurs with heart disease. However, not all individuals with the same heart abnormalities suffer from AF. Similarly, catheter ablation successfully treats AF in some people, but in others AF recurs after ablation. These observations indicate a possible genetic predisposition that could determine whether an individual is prone to develop AF or not, as well as the outcome of an ablation procedure.

This prospective pilot study will examine the association of specific genetic variants (single nucleotide polymorphisms) located on chromosome 1, 4 and 16, with presence of NPVT, as well as ablation outcome in AF patients.

Dobutamine versus isoproterenol for inducibility of atrial arrhythmias in atrial fibrillation ablation

During an atrial fibrillation (AF) ablation procedure, a medication called isoproterenol is used to stimulate atrial arrhythmias (abnormal rhythms in the upper chambers of the heart) and identify potential targets for ablation. This study is being conducted to evaluate an alternative medication called dobutamine. Both isoproterenol and dobutamine increase the strength and rate of the heart’s pumping action. Sometimes isoproterenol can lower blood pressure by relaxing blood vessels. Dobutamine does not have this effect. Otherwise, the medications are similar.

The purpose of this research study is to collect data on the use of dobutamine as an alternative to isoproterenol to cause atrial arrhythmias during AF ablation

EpiEP EpiAccess

The purpose of this registry is to collect long term information to confirm the safety and effectiveness of using a new type of pericardial access device (whose name is EpiAccess). The EpiAccess System is a specialized system that assists your doctor in understanding when they are in this anatomical location around your heart. “Pericardial Access” is a term which defines access to the sac around your heart which allows the physician to place the catheters to perform catheter ablation.

The EpiAccess device has been approved by the United States Food and Drug Administration (FDA) for use in participants.

FIX-HF - Evaluation of the Safety and Efficacy of the OPTIMIZER™ System with Active Fixation Leads in Subjects with Heart Failure Resulting from Systolic Dysfunction

The purpose of this research study is to evaluate the safety and effectiveness of the OPTIMIZER system. The OPTIMIZER system has been developed to improve heart strength by stimulating the heart muscle with an electrical signal. It delivers ‘cardiac contractility modulation’ (CCM) treatment.

This study is currently in follow-up only and is not enrolling new patients.

HERITAGE - Heritable Arrhythmia Genetics

The purpose of this study is to evaluate the genetics (the genes and how they are inherited) of the following inheritable arrhythmias: Brugada syndrome, Wolf-Parkinson-White Syndrome, Idiopathic Ventricular Tachycardia and Fibrillation, Long QT Syndrome, Hypertrophic, Dilated and Restrictive Cardiomyopathy and Supraventricular Tachycardia. By studying your DNA, the gene(s) responsible for inherited arrhythmias may be able to be identified. There are no medications or devices being investigated in this study. The study will enroll patients with an inheritable arrhythmia (an abnormal heart rhythm) and participation will last for up to 2 days.

HFIB - Adjunctive Renal Denervation to Modify Hypertension and Sympathetic Tone As Upstream Therapy in the Treatment of Atrial Fibrillation

This study is being done to determine if an investigational procedure called Renal Sympathetic Denervation (RSDN) can decrease the recurrence of Atrial Fibrillation (AFib), and help control your high blood pressure. It seeks to determine the role of RSDN in the prevention of Afib recurrence in patients with high blood pressure when using the VessixTM Renal Denervation System (Boston Scientific). It will enroll patients who are scheduled to undergo an ablation procedure to treat Atrial Fibrillation (AFib), and have high blood pressure.

Janssen smartADHERE -Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

The purpose of this study is to evaluate the effectiveness of an intervention with a mobile phone medication reminder application, compared to physician-or nurse-guided standard of care, to improve adherence to rivaroxaban in subjects who have recently begun treatment with rivaroxaban for stroke prevention in atrial fibrillation (AF). The mobile (smartphone) application used in this study is called Care4Today®Mobile Health Manager. It is designed to assist patients with adhering to their medication schedule.

This study will enroll approximately 378 patients who have a diagnosis of AF, have recently begun or been prescribed Rivaroxaban for stroke prevention, and have a smartphone with an active data plan. Participation would last approximately 6 months. The study will take place in the US only.

Lifestyle AF - Impact of Lifestyle Modification On Ablation Outcome in Atrial Fibrillation

The purpose of this research study is to evaluate the impact of aggressive lifestyle modification on the outcome of atrial fibrillation (AF) ablation in overweight and obese patients with AF by using diet and exercise. It will enroll patients that have chronic (long term) AF, and are scheduled to undergo an ablation procedure to treat the AF. You will undergo different levels of diet consultation and exercise to determine their effect on the outcome of the ablation procedure.

MAGNETIC-VT - comparing VT ablation outcomes using remote MAGNETIC navigation guided substrate mapping and ablation versus manual approach in a low LVEF population

This prospective, multi-center, post market randomized trial will compare the outcomes of Ventricular Tachycardia (VT) ablation using standard manual placement of the catheter versus magnetic placement of the catheter using the Niobe™ ES MAGNETIC catheter system. This system allows the doctor to remotely maneuver the catheter, rather than move it manually.

The study will enroll patients who are scheduled to undergo an ablation procedure to treat VT and have an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) who have also experiences a myocardial infarction (MI) or ‘heart attach’ that resulted in scar tissue.

All ablation equipment used in this study is approved by the United States Food and Drug Administration (FDA).

Medtronic ADAPT Response Study

A CRT device feature called AdaptivCRT (aCRT) will be evaluated in this study. It is designed to automatically optimize CRT pacing therapy by observing patterns in your heart’s contractions and then automatically adjusting your CRT device settings. Currently, an echocardiogram (ultrasound of the heart) or an ECG (records the electrical tracing of the heart’s activity) may be used to provide information needed to program CRT devices. Another option is to use the standard factory settings. This study will investigate the benefits of the aCRT feature compared to these other methods. The aCRT feature is used in addition to standard CRT therapy.

Medtronic Attain StabilityTM Quad Clinical Study

This study is for patients who are receiving a Cardiac Resynchronization Therapy (CRT) system or a CRT system upgrade to treat heart failure. The purpose of this study is to evaluate the safety and efficacy of the investigational Attain Stability Quad MRI SureScan Left Ventricular (LV) Lead. If you participate in the study, you will receive the investigation LV lead. The Attain Stability™ Quad MRI SureScan LV Lead (“study lead”) is similar to other FDA approved LV leads but also has a feature that is used to ensure the lead stays in place.

The Attain Stability Quad Clinical Study is a prospective, non-randomized, multi-site, global, Investigational Device Exemption (IDE) interventional clinical study and will enroll approximately 471 patients worldwide.

Medtronic Product Surveillance Registry

The primary purpose of this prospective, non-randomized, multi-center study is to evaluate and publish the long-term reliability and performance of Medtronic market-released cardiac therapy products by analyzing product survival probabilities. Product-related adverse events, indicating the status of the product, will be collected to measure survival probabilities. The data gathered in this study may also be used to support the design and development of investigational plans for new cardiac therapy products.

NAVIGATE x4 - Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads

The purpose of this research study is to evaluate the safety and effectiveness of the LV lead (ACUITY x4), and RV lead(RELIANCE 4-FRONT), and the CRT-D device (AUTOGEN™ X4CRT-D). For this study, the programmer will use investigational software to communicate with the CRT-D. The study will enroll patients who are scheduled to receive an Implantable Cardioverter Defibrillator (ICD) which provides ‘Cardiac Resynchronization Therapy’ (CRT). The LV lead, CRT-D, and programmer software are investigational, which means they are not approved by the approved by the United States Food and Drug Administration (FDA). The right upper chamber lead used in this study is approved by the FDA and is commercially available. This study is currently in follow-up only and is not enrolling new patients.

NGEVITY Active Fixation and Passive Fixation Pace/ Sense Lead Study

Our research group is collaborating with Texas Heart and Vascular – Austin on this study. The purpose of this study is to evaluate the safety, performance, and effectiveness of a new lead, called INGEVITY. Standard pacemaker systems consist of a pacemaker device and up to three special wires (leads) that connect the pacemaker to your heart. The pacemaker senses your heart’s own electrical signals and then paces your heart, if it skips a beat, by giving a small electrical impulse through the lead, which you won’t feel. Patients enrolled into this clinical study will have approved indications for a pacemaker or cardiac resynchronization pacemaker (CRT-P) IPG and will be implanted with one or two leads from the INGEVITY Lead family.

This study is currently in follow-up only and is not enrolling new patients.

OAT - Safety of Oral Anticoagulation Therapy withdrawal after successful Pulmonary Vein Antrum Isolation in Patients with Atrial Fib and Associated High Risk Factors for Embolic Events

Patients who have undergone successful PVAI for symptomatic high-burden paroxysmal AF refractory to antiarrhythmic drug (AAD) therapy will be randomized (1:1) to one of two study arms: (1) OAT Withdrawal (Test) Group or (2) OAT (Control) Group. Hypothesis: High risk subjects who have successful PV antrum isolation and remain free from AF recurrence for 9-21 months post ablation procedure can discontinue their OAT without an increased risk of thromboembolic events as compared to those who remain on OAT.

PRECEPT - Prospective Review of the Safety and Effectiveness of the SMARTTOUCH SF Catheter Evaluated for Treating Symptomatic Persistent AF

This is a multicenter, non-randomized clinical evaluation to demonstrate the safety and effectiveness of the ThermoCool SMARTTOUCH SF catheter when used to treat persistent atrial fibrillation (AF). The ablation catheter contains a sensor at the tip that measures pressure the catheter tip exerts on the heart tissue and may make it easier for your doctor to determine the best position of the catheter, thereby simplifying or shortening the procedure. It is considered investigational which means it is not approved by the United States Food and Drug Administration (FDA).

PREVENT VT - Prophylactic Cervicothoracic Sympathectomy for Prevention of Ventricular Tachycardia

The purpose of this study to evaluate an additional therapy option for recurrent ventricular tachycardia (VT) called cervicothoracic sympathectomy (CTS). Research has shown that a group of nerves called a ganglia feeding the lower chambers of the heart (ventricles) help start and maintain VT. A surgical procedure called CTS removes a section of these nerves. The goal of this study is to determine whether CTS can prevent VT from occurring, and therefore prevent ICD shocks.

PROMUS Element Plus US Post-Approval Study

The main purpose of this study is to collect more information a drug-eluting stent, called the PROMUS Element Everolimus-Eluting Platinum Chromium Coronary Stent (or Promus Element stent) system, details of the stent procedure, and information about the patients who are treated with this stent. The Promus Element stent has been developed by Boston Scientific Corporation, the company that is sponsoring this study. The PROMUS Element stent is coated with medication (Everolimus). Studies have shown this medication helps to prevent restenosis or re-blockages within stents. The stent is made of platinum and chromium. The stent is designed to improve the way your doctor can deliver the stent in the diseased artery.

This study is currently in follow-up only and is not enrolling new patients.

RESCUE - Renal Sympathetic Denervation to Suppress Tachyarrhythmias in ICD Recipients

In this current multicenter trial, called RESCUE, persons who are receiving an ICD will be randomly assigned (like the flip of a coin) to either the denervation procedure or nothing further.

Recently, there is a new procedure called renal sympathetic denervation (RSDN) that is being used in patients with high blood pressure, but may also help prevent ICD shocks in patients like you. This procedure involves placing a catheter within the arteries that supply blood to the kidneys and cauterizing (applying heat) to the wall of the vessel. This affects nerves that travel in the walls of these arteries and send information back and forth from the kidney and brain. Studies have shown that using heat to deactivate these nerves decreases the activity of the sympathetic nervous system (the nerves that control the release of adrenaline-like hormones in the body). We believe that by doing this denervation procedure, we may be able to decrease the need for the ICD to shock you. In the ideal situation, the denervation procedure will largely prevent the abnormal heart beats, and the ICD will simply be there as back-up therapy.

SAMURAI - ImageReady™ MR Conditional Pacing System

The purpose of this study is to evaluate the safety, performance, and effectiveness of a pacemaker called VITALIO MRI, the lead called INGEVITY MRI, and the piece of rubber called a ‘suture sleeve’ which secures the lead to your body. It will enroll patients who are scheduled to undergo the implantation of a pacemaker and will evaluate the investigational pacemaker system which allows patients to undergo a magnetic resonance imaging (MRI) scan.

These devices are investigational, which means they are not approved by the United States Food and Drug Administration. This study is currently in follow-up only and is not enrolling new patients.

Siemens P6 - Assessment of the utility of the Siemens P6 volume ICE catheter in electrophysiology and structural heart disease procedures

This study is for patients that are scheduled to undergo Atrial Fibrillation (AF) ablation, Ventricular Tachycardia (VT) ablation, or implantation of a Left Atrial Appendage LAA) occluder. During these procedures, the doctor uses an ultrasound catheter inside the heart to maintain images of the heart throughout the procedure. This is known as an intracardiac echocardiogram (ICE). The P6 ICE catheter that will be evaluated in this study offers a larger field of view. The purpose of this research study is to better understand the role and impact of the Siemens volume ICE P6 catheter technology in AF and VT ablation procedures and LAA procedures.

St. Jude AMULET - Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial

This study is for patients that have nonvalvular atrial fibrillation (AF) and are scheduled to receive a Boston Scientific WATCHMAN LAA occluder device. It is evaluating the AMPLATZER™ Amulet™Left Atrial Appendage Occluder device (AMULET). Like the WATCHMAN device, the AMULET device is designed to reduce the risk of a blood clot from the left atrial appendage (LAA). This purpose of this prospective, randomized, multicenter, active control worldwide trial is to find out if the AMULET device is safe and effective when compared to the WATCHMAN.

STROKE-VT - Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation

Apixaban is a blood thinning drug, also called an anticoagulant. It interferes with the body’s natural blood clotting ability by inactivating a specific enzyme that the body needs to form blood clots. This multicenter, randomized, prospective study will evaluate whether Apixaban, given orally before and after an ablation procedure is more effective than Aspirin at preventing blood clots from forming, and therefore lowering the chance of a stroke in ventricular tachycardia (VT) ablation patients.

Tacticath PAS - Tacticath Contact Force Ablation Catheter Study for Atrial Fibrillation

The purpose of this post-approval research study is to collect additional data about the safety and effectiveness of the St. Jude TactiCath Quartz® Set (TactiCath Quartz® Catheter and TactiSys Quartz® Ablation System) when used to treat AF. The set, which consists of an ablation catheter and energy generator, is approved by the United States Food and Drug Administration (FDA). There are no investigational devices used in this study. This study is currently in follow-up only and is not enrolling new patients.

Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

Ablation uses focused electrical energy known as radiofrequency (RF) energy to burn or ‘ablate’ portions of the tissue inside of the heart to stop the AF and restore a normal heart rhythm. In addition to using RF, our doctors are evaluating the use of alcohol injected into a
vein in your heart called the Vein of Marshall (VOM) in addition to your standard catheter ablation procedure.

The purpose of this research study is to determine if a standard ablation procedure combined with alcohol infusion in the Vein of Marshall is more successful than a standard ablation alone. The use of alcohol for AF ablation is investigational, which means it is not approved by the United States Food and Drug Administration (FDA).

Watchman CAP2 - Continued access to Watchman PREVAIL

The study will enroll patients who have a heart condition in which the upper chambers of the heart beat too fast. This condition, known as atrial fibrillation (AFib), can cause blood clots to form in an area of your heart called the left atrial appendage (LAA). It is believed that if the LAA pouch in the heart is closed, then blood clots might not be able to form in that area. This research study will evaluate an investigational device called the WATCHMAN®. The WATCHMAN® device is a round filter designed to exclude or block off the LAA (pouch) and prevent the release of blood clots into the circulatory (blood) system. This device is designed to be permanently implanted in the LAA (pouch) of the heart to prevent stroke without the need for long-term anti-coagulation blood thinners such as warfarin (Coumadin®).

This study is currently in follow-up only and is not enrolling new patients.

ZODIAC - Pulmonary Vein reconnection after Pulmonary Vein Antrum Isolation at different power settings using adenosine provocation

This is a prospective, randomized, multi-center study is designed to find the optimal ablation energy strategy, and compare the rate of atrial fibrillation (AF) recurrence following ablation of the pulmonary veins (PVs) and posterior wall. The ablation is performed at different energy settings, 30 watts versus 40 watts.

Meet Our Physicians

Meet Our Physicians

Learn About Heart Rhythm Disorders

Learn About Heart Rhythm Disorders

Review Our Procedures

Review Our Procedures

Meet Dr. Andrea Natale

Meet Dr. Andrea Natale

Our Latest News

Our Latest News